● Recruiting

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

Condition: Solid Tumor Cancer · Solid Tumor Cancer Treatment With Immunotherapy · Sponsor: Jun Zhou

PhasePhase 1

Planned participants90

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor

This description comes directly from the study's public registry record.

Talk to the study team

Jun Zhou, Ph.D · (+86)18018182095 · jun_zhou@immunourchin.com

Always discuss trial participation with your own doctor first.

Locations (6)

Fujian Cancer Hospital	Fuzhou, Fujian, China	Recruiting
Anyang tumor hospital	Anyang, Henan, China	Recruiting
Cancer hospital of Shandong First Medical University	Jinan, Shandong, China	Recruiting
Fudan University Shanghai cancer center	Shanghai, China	Recruiting
Shanghai Pulmonary hospital	Shanghai, China	Recruiting
Shanghai Xinhua hospital	Shanghai, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07584954